Concealed Long-QT Syndrome with Rare KCNQ1 Gene Mutation in an Elderly Female: A Case Report
DOI:
https://doi.org/10.59958/hsf.6803Keywords:
long QT syndrome, KCNQ1, electrocardiogramAbstract
Long QT syndrome (LQTS) is a hereditary disorder that can lead to recurrent syncope, convulsive episodes, and sudden death due to ventricular arrhythmia. In most instances, LQTS remains concealed and primarily presents as unexplained syncope despite have a normal electrocardiogram (ECG) during periods of rest. This characteristic can be highly deceptive and may result in severe and potentially fatal consequences if treated incorrectly. In this report, we present a case of concealed LQTS in an elderly female patient who experienced an initial episode of syncope at the age of 76. Upon admission, the surface ECG showed no abnormalities. However, during the bedside ECG examination, typical manifestations of LQTS were detected, indicating an early stage of the ictal process. Subsequent treatment with βblockers provided symptomatic relief. Genetic testing identified a rare mutation, p. Arg366Trp (with a c.1096C>T variant), in the KCNQ1 gene, confirming the diagnosis of LQTS. Although congenital LQTS cases are more commonly found in young females, the potential for LQTS should not be overlooked in elderly patients who complain of unexplained syncope, even if their ECG normal. The use of an artificial intelligence (AI)-based diagnostic tool has the potential to offer a more precise means of identifying concealed LQTS in the future, but, until now, thorough examination and close observation during admission is necessary to avoid missed diagnoses of the concealed LQTS-syndrome.
References
Bohnen MS, Peng G, Robey SH, Terrenoire C, Iyer V, Sampson KJ, et al. Molecular Pathophysiology of Congenital Long QT Syndrome. Physiological Reviews. 2017; 97: 89–134.
Newton-Cheh C, Eijgelsheim M, Rice KM, de Bakker PIW, Yin X, Estrada K, et al. Common variants at ten loci influence QT interval duration in the QTGEN Study. Nature Genetics. 2009; 41: 399–406.
Schwartz PJ, Ackerman MJ. Cardiac sympathetic denervation in the prevention of genetically mediated life-threatening ventricular arrhythmias. European Heart Journal. 2022; 43: 2096–2102.
Priori SG, Schwartz PJ, Napolitano C, Bloise R, Ronchetti E, Grillo M, et al. Risk Stratification in the Long-QT Syndrome. New England Journal of Medicine. 2003; 348: 1866–1874.
Splawski I, Shen J, Timothy KW, Vincent GM, Lehmann MH, Keating MT. Genomic Structure of Three Long QT Syndrome Genes: KVLQT1, HERG, and KCNE1. Genomics. 1998; 51: 86–97.
Krahn AD, Laksman Z, Sy RW, Postema PG, Ackerman MJ, Wilde AAM, et al. Congenital Long QT Syndrome. JACC: Clinical Electrophysiology. 2022; 8: 687–706.
Schwartz PJ, Crotti L. QTc Behavior during Exercise and Genetic Testing for the Long-QT Syndrome. Circulation. 2011; 124: 2181–2184.
Saenen JB, Vrints CJ. Molecular aspects of the congenital and acquired Long QT Syndrome: Clinical implications. Journal of Molecular and Cellular Cardiology. 2008; 44: 633–646.
Ackerman MJ, Priori SG, Willems S, Berul C, Brugada R, Calkins H, et al. HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). Heart Rhythm. 2011; 8: 1308–1339.
Crotti L, Lundquist AL, Insolia R, Pedrazzini M, Ferrandi C, De Ferrari GM, et al. KCNH2-K897T is a genetic modifier of latent congenital long-QT syndrome. Circulation. 2005; 112: e294.
Turker I, Ai T, Itoh H, Horie M. Drug-induced fatal arrhythmias: Acquired long QT and Brugada syndromes. Pharmacology and Therapeutics. 2017; 176: 48–59.
Shimizu W, Noda T, Takaki H, Kurita T, Nagaya N, Satomi K, et al. Epinephrine unmasks latent mutation carriers with LQT1 form of congenital long-QT syndrome. Journal of the American College of Cardiology. 2003; 41: 633–642.
Walker BD, Krahn AD, Klein GJ, Skanes AC, Yee R. Burst bicycle exercise facilitates diagnosis of latent long QT syndrome. American Heart Journal. 2005; 150: 1059–1063.
Prifti E, Fall A, Davogustto G, Pulini A, Denjoy I, Funck-Brentano C, et al. Deep learning analysis of electrocardiogram for risk prediction of drug-induced arrhythmias and diagnosis of long QT syndrome. European Heart Journal. 2021; 42: 3948–3961.
Aufiero S, Bleijendaal H, Robyns T, Vandenberk B, Krijger C, Bezzina C, et al. A deep learning approach identifies new ECG features in congenital long QT syndrome. BMC Medicine. 2022; 20: 162.
Bos JM, Attia ZI, Albert DE, Noseworthy PA, Friedman PA, Ackerman MJ. Use of Artificial Intelligence and Deep Neural Networks in Evaluation of Patients with Electrocardiographically Concealed Long QT Syndrome from the Surface 12-Lead Electrocardiogram. JAMA Cardiology. 2021; 6: 532–538.
Doldi F, Plagwitz L, Hoffmann LP, Rath B, Frommeyer G, Reinke F, et al. Detection of Patients with Congenital and Often Concealed Long-QT Syndrome by Novel Deep Learning Models. Journal of Personalized Medicine. 2022; 12: 1135.
Schwartz PJ, Spazzolini C, Priori SG, Crotti L, Vicentini A, Landolina M, et al. Who are the long-QT syndrome patients who receive an implantable cardioverter-defibrillator and what happens to them?: data from the European Long-QT Syndrome Implantable Cardioverter-Defibrillator (LQTS ICD) Registry. Circulation. 2010; 122: 1272–1282.
Wang M, Peterson DR, Rosero S, McNitt S, Rich DQ, Seplaki CL, et al. Effectiveness of Implantable Cardioverter-Defibrillators to Reduce Mortality in Patients with Long QT Syndrome. Journal of the American College of Cardiology. 2021; 78: 2076–2088.
